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Type VII collagen, the major component of anchoring
fibrils, consists of a central collagenous triple-helical
domain flanked by two noncollagenous, globular
domains, NC1 and NC2. Approximately 50% of the
molecular mass of the molecule is consumed by the
NC1 domain. We previously demonstrated that NC1
binds to various extracellular matrix components
including a complex of laminin 5 and laminin 6 (Chen
et al, 1997a). In this study, we examined the interaction
of NC1 with laminin 5 (a component of anchoring
filaments). Both authentic and purified recombinant
NC1 bound to human and rat laminin 5 as measured
by enzyme-linked immunosorbant assay and by bind-
ing of 125I-radiolabeled NC1 to laminin 5-coated wells,
but not to laminin 1 or albumin. NC1 bound predomi-
nantly to the b3 chain of laminin 5, but also to the g2
chain when examined by a protein overlay assay. The
The epidermis and dermis of human skin are separatedby a complex zone called the dermal–epidermaljunction (DEJ) that contains a basement membrane(Briggaman and Wheeler, 1975). Many DEJ compon-ents are synthesized by keratinocytes within the
epidermis, including type VII collagen (Stanley et al, 1985; Woodley
et al, 1985). When viewed by electron microscopy, discrete
structures within the DEJ are identified. These include hemidesmo-
somes associated with the plasma membrane of the basal
keratinocytes apposed to the DEJ; a 35–50 nm lucent space called
the lamina lucida that contains delicate filaments called anchoring
filaments; a 35–50 nm electron dense zone called the lamina densa
and wheat-stack shaped structures called anchoring fibrils that
emanate perpendicularly beneath the lamina densa (Briggaman and
Wheeler, 1975). The main component of anchoring fibrils is type
VII collagen (Sakai et al, 1986; Keene et al, 1987), whereas the
main component of anchoring filaments is laminin 5 (formerly
known as kalinin, nicein, and epiligrin) (Rousselle et al, 1991).
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binding of 125I-NC1 to laminin 5 was inhibited by a
50-fold excess of unlabeled NC1 or de-glycosylated
NC1, as well as a polyclonal antibody to laminin 5 or
a monoclonal antibody to the b3 chain. In contrast,
the NC1–laminin 5 interaction was not affected by a
monoclonal antibody to the a3 chain. Using NC1
deletion mutant recombinant proteins, a 285 AA
(residues 760–1045) subdomain of NC1 was identified
as the binding site for laminin 5. IgG from an epiderm-
olysis bullosa acquisita serum containing autoantibod-
ies to epitopes within NC1 that colocalized with the
laminin 5 binding site inhibited the binding of NC1
to laminin 5. Thus, perturbation of the NC1–laminin
5 interaction may contribute to the pathogenesis of
epidermolysis bullosa acquisita. Key words: autoantibod-
ies/epidermolysis bullosa/extracellular matrix components. J
Invest Dermatol 112:177–183, 1999
Recently, using unfixed frozen skin, this traditional organization
of the DEJ has been challenged (Keene and McDonald, 1993;
Kivirikko, 1993). This neatly organized zone viewed by electron
microscopy may be an artifact of the fixation process, and the true
DEJ organization may allow much closer apposition of various DEJ
components. In the traditional view of the DEJ, anchoring filaments
are separated from anchoring fibrils by the lamina densa, a structure
that is rich in type IV collagen and proteoglycans (Stanley et al,
1982). It may be, however, that in reality there is apposition
between anchoring filaments and anchoring fibrils, both structures
that are thought to be critical for maintenance of epidermal–dermal
adherence. Gene defects in components of either structure, namely
laminin 5 or type VII collagen, are associated with severe incurable
blistering disorders of the skin (Uitto et al, 1994).
Laminin 5 consists of three nonidentical chains: α3 (200 kDa),
β3 (140 kDa), and γ2 (155 kDa), each encoded by a distinct gene
(Kallunki et al, 1992; Gerecke et al, 1994; Ryan et al, 1994).
Laminin 5 supports epithelial cell adhesion by interacting with the
α6β4 and α3β1 integrin receptors on basal keratinocytes (Carter
et al, 1990, 1991; Niessen et al, 1994). It also forms complexes
with other laminin isoforms such as laminin 6 and laminin 7
(Champliaud et al, 1996). Therefore, laminin 5 has both matrix
and cell binding capabilities. Autoantibodies to the α3 chain are
associated with a severe autoimmune blistering disease of the
mucosa called cicatricial pemphigoid (Domloge-Hultsch et al, 1992;
Kirtschig et al, 1995; Chan et al, 1997). Defects in the genes
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encoding for laminin 5 result in a severe inherited blistering disease
of the skin called junctional epidermolysis bullosa (Aberdam et al,
1994; Pulkkinen et al, 1994a, b). The cleavage plane of junctional
epidermolysis bullosa blisters is through the lamina lucida where
anchoring filaments are localized. Because junctional epidermolysis
bullosa patients also have perturbations in hemidesmosomes associ-
ated with a paucity of laminin 5 and anchoring filaments, there is
direct evidence that anchoring filaments and laminin 5 may have
a role in the initiation or maintenance of hemidesmosome structures,
possibly by interactions with the α6β4 and α3β1 integrins (Baker
et al, 1996b).
Type VII collagen is composed of three identical alpha chains
encoded by chromosome 3. Each chain consists of a central helical
domain flanked by a large amino-terminal noncollagenous domain
(NC1) and a smaller carboxyl-terminal noncollagenous domain
(NC2) (Lunstrum et al, 1986, 1987; Burgeson et al, 1990; Parente
et al, 1991; Christiano et al, 1992, 1994). The larger NC1 domain
(Mr 5 145,000) contains motifs that are similar to fibronectin type
III-like repeats (FNIII), the A domain of von-Willebrand factor
(VWF-A), and cartilage matrix protein, all elements with known
adhesive properties (Christiano et al, 1992, 1994). Therefore, it is
conceivable that NC1 serves to mediate interactions between type
VII collagen and other matrix components. Mutations in the gene
encoding type VII collagen result in a family of severe blistering
skin diseases called dystrophic epidermolysis bullosa, characterized
by a paucity of normal anchoring fibrils (Uitto and Christiano,
1993, 1994). Autoantibodies to type VII collagen are associated
with an acquired autoimmune form of EB, epidermolysis bullosa
acquisita (EBA) (Woodley et al, 1984, 1988).
Previously, using full-length recombinant NC1, we demonstrated
that its structural and functional properties were identical to
authentic NC1 (Chen et al, 1997a). We (Chen et al, 1997a) and
others (Burgeson et al, 1990) have shown that NC1 binds to
fibronectin, type I collagen, and type IV collagen. We also
demonstrated that NC1 binds to a complex of laminin 5 and
laminin 6 (Chen et al, 1997a). In the study described herein, we
focused on the interaction between NC1 and purified laminin 5.
Using three independent binding assays, combined with the use of
deletional mutants within NC1, we demonstrate that NC1 binds
to laminin 5 and that this binding is mediated predominantly by
the β3 chain of laminin 5 and selected FN motifs within NC1.
These data, taken together with the clinical observations that
patients with gene defects in either laminin 5 or type VII collagen
exhibit incurable blistering disorders of the skin, suggest that the
interaction between laminin 5 and type VII collagen may be very
important for the maintenance of epidermal–dermal adherence in
human skin. In addition, we demonstrated that autoantibodies
against the NC1 domain of type VII collagen in the serum of a
patient with EBA inhibit the binding of NC1 to laminin 5, whereas
IgG from normal human serum does not inhibit this interaction.
Therefore, if the NC1–laminin 5 interaction is important for
epidermal–dermal adherence, the presence of EBA autoantibodies
may be detrimental to this adherence.
MATERIALS AND METHODS
Materials Mouse laminin 1 was prepared from the EHS tumor as
described (Woodley et al, 1983) and human laminin 1 was obtained from
Gibco-BRL (Gaithersburg, MD). Human laminin 5 was purified from
keratinocyte medium by antibody affinity chromatography using MoAb
K140-sepharose (Marinkovich et al, 1992) or prepared from cultures of
human keratinocytes by sequential extraction as described previously (Carter
et al, 1991). Rat laminin 5 was isolated from the medium of 804G cells
by column chromatography and was provided by Desmos (San Diego,
CA) (Baker et al, 1996a).
The recombinant NC1 domain of human type VII collagen was purified
from serum-free culture medium of human 293 cells stably transfected
with NC1 cDNA as described (Chen et al, 1997a). Purification of the
authentic NC1 from collagenase digests of human amnion was accomplished
as described previously using affinity chromatography with coupled mono-
clonal antibodies NP185 and NP32 (Bachinger et al, 1990).
Antibodies The experimental antibodies used in this study include: (i)
a murine monoclonal antibody, LH 7.2, which specifically recognizes the
NC1 domain of type VII collagen (Lapiere et al, 1994); (ii) a murine
monoclonal antibody, K140, which specifically recognizes the β3 chain of
human laminin 5 (Marinkovich et al, 1992); (iii) a murine monoclonal
antibody, BM165, which specifically recognizes the α3 chain of human
laminin 5 (6); (iv) a rabbit polyclonal antibody, J-18, which recognizes
both rat and human laminin 5 (Langhofer et al, 1993); (v) a polyclonal
antibody to the β3 chain and a polyclonal antibody to the γ2 chain of
human laminin 5 (generously supplied by Dr. Warren Hoeffler, Stanford
University); and (vi) sera obtained from a patient with EBA and from a
healthy volunteer, who served as a control. This EBA serum demonstrated
strong reactivity with immobilized NC1 in an enzyme-linked immunosorb-
ant assay and by immunoblot analysis (Chen et al, 1997b). The IgG fractions
from these two sources were partially purified by affinity chromatography
using Protein G Sepharose 4 (Pharmacia, Piscataway, NJ) according to
the manufacturer’s instructions. The IgG fractions, after dialysis against
phosphate-buffered saline, were concentrated by ultrafiltration to 100 mg
per ml (Amicon, Beverly, MA) and stored at –20°C.
Proteins binding assays
Enzyme-linked immunosorbant assay Binding of soluble NC1 to immobil-
ized ligands followed by a colorimetric enzyme-linked antibody reaction
was performed as previously described (Woodley et al, 1983; Chen et al,
1997a). Multiwell plates (96 wells, Dynatech, Chantilly, VA) were coated
overnight with purified laminin isoforms (1 µg) in 100 mM carbonate
buffer, pH 9.3. The wells were then blocked with 1% bovine serum
albumin (BSA) in phosphate-buffered saline, 0.05% Tween-20 (PBST).
Coated wells were subsequently incubated with purified recombinant NC1
at a concentration of 20 µg per ml overnight at 4°C. The binding of NC1
to each laminin isoform was detected with a monoclonal anti-type VII
collagen antibody, LH 7.2 (Sigma, St. Louis, MO), at a dilution of 1:300,
followed by incubation with alkaline phosphatase-conjugated goat anti-
mouse IgG (1:400) (Organon Teknika-Cappel, Durham, NC). The devel-
opment of the colorimetric reaction using p-nitro-phenylphosphate as a
substrate (Bio-Rad, Melville, NY) was measured by reading the absorbance
of the product at 405 nm (Labsystems Multiskan Multisoft, Finland).
Radiolabeled protein binding assay Purified recombinant NC1 was labeled
with 125I by iodination with IODO-BEADS according to the manufac-
turer’s instructions (PIERCE, Rockford, IL). 125I Labeled NC1 was then
separated from free iodine by chromatography over a D-Salt Excellulose
column (PIERCE). The radiolabeled NC1 preparations were characterized
for purity by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) on a 6% slab gel. Dried gels were subjected to autoradiography.
The iodinated NC1 was stored in aliquots at –70°C.
Ninety six well plates were coated with 1 µg of albumin or various
purified laminin isoforms in 100 mM carbonate buffer, pH 9.3 overnight
at 4°C. The wells were then blocked with 1% albumin in PBST for 2 h.
125I-labeled NC1 was added to each well in 100 µl PBST at concentrations
between 10 and 150 ng and incubated for 4 h at 4°C. Unbound protein
was removed and the wells washed three times with PBST. Radiolabeled
NC1 bound to the substratum of each well was detected by solubilizing
the proteins by the addition of 100 µl of 2% SDS, 25 mM Tris-HCl,
150 mM NaCl, 5 mM ethylenediamine tetraacetic acid to each well,
incubating the wells for 2 h at room temperature and counting the bound
radioactivity in scintillation fluid with a gamma-counter (Beckman).
Western blots labeled with 125I-NC1 Protein-to-protein affinity by
western blot analysis was performed as previously described (Woodley et al,
1987). Briefly, 2 µg of human or rat laminin 5, human or mouse laminin
1, BSA, fibronectin, and type IV collagen were reduced with 2 mM
dithiothreitol followed by SDS-PAGE and electrophoretic transfer to
nitrocellulose. The blots were blocked with PBST/3% BSA overnight at
4°C, washed three times in PBST, and incubated with µ500,000 cpm per
ml of 125I-labeled NC1 in PBST containing 1% BSA for 4 h at room
temperature. After the incubation, the blots were washed extensively in
PBST, air-dried, and subjected to autoradiography.
For the EBA serum inhibition assay, 125I-labeled NC1 was preincubated
with IgG from EBA serum or control IgG from normal human serum
(100 µg per ml) for 2 h at room temperature before being added to the
nitrocellulose strips containing laminin 5.
Construction and expression of deletion recombinant NC1
proteins The eukaryotic expression vector containing the full-length
human NC1 domain was described previously (Chen et al, 1997a). In this
study, we used the expression vector containing the full-length NC1
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cDNA in the TA vector (Invitrogen, San Diego, CA) as a template to
prepare two additional deletional constructs by digesting the template with
various restriction enzymes, including Xho I and Bst XI. All constructs
were then inserted into the Hind III/Xba I-digested eukaryotic expression
vector pRC/CMV (Invitrogen). cDNA constructs were transfected into
the human embryonic kidney cell line 293 (ATCC, Rockville, MD). G418
resistant cell clones were then selected and screened for expression of the
deletion proteins by immunoblot analysis with a mouse monoclonal
antibody, LH 7.2 (1:200) (Sigma), against the NC1 domain of type VII
collagen. Secreted recombinant proteins were collected from conditioned
medium from confluent cell cultures grown for 2 d in serum-free culture
medium and purified as described previously (Chen et al, 1997a). These
recombinant proteins include full-length NC1 (residues 1–1253), and two
diminutive NC1 proteins created by deletions in the NC1 cDNA: NC1-
S1 (residues 1–1045) and NC1-S2 (residues 1–760).
Bacterial fusion proteins corresponding to discrete segments within the
NC1 domain of type VII collagen were developed and purified by a
glutathione-Sepharose 4B column (Pharmacia, Uppsala, Sweden) as
described (Lapiere et al, 1993). These fusion proteins included FP1 (residues
201–602), FP3 (residues 595–826), FP7 (residues 814–1028), and FP8
(residues 1022–1253).
RESULTS
Binding of NC1 to laminin 5 immobilized on plastic We
previously demonstrated that recombinant and authentic NC1
interact with a laminin 5/6 complex (Chen et al, 1997a). In this
study, we sought to determine if NC1 could bind directly to
laminin 5. We examined the binding of both recombinant NC1
and authentic NC1 to immobilized laminin 5 by enzyme-linked
immunosorbant assay. As shown in Fig 1(A), both recombinant
NC1 and authentic NC1 bound to human laminin 5 or rat laminin
5. In contrast, little or no binding occurred to human laminin 1
or mouse laminin 1. There was no significant difference in the
binding affinity for laminin 5 when authentic and recombinant
NC1 were compared. Both rat laminin 5 and human laminin 5
bound to NC1 with comparable potency.
The binding of 125I-NC1 to immobilized laminin 5 was also
examined with a second type of solid phase assay. As shown in
Fig 1(B), 125I-labeled NC1 bound to both human laminin 5 and
rat laminin 5 in a concentration-dependent manner. The binding
of NC1 to control wells coated with BSA was negligible. The
level of binding to laminin 1 and type V collagen was equivalent
to BSA (data not shown).
We next examined the ability of unlabeled NC1 and anti-laminin
5 antibodies to inhibit specifically the interaction between NC1
and laminin 5. J-18 is an anti-laminin 5 polyclonal antibody that
strongly recognizes the β3 and γ2 chains of human laminin 5 and
weakly recognizes the α3 and α3* (processed α3 chain) of human
laminin 5 (Langhofer et al, 1993) (Fig 2A, lane 3). The identities
of the β3 and γ2 chain were confirmed by immunoblotting with
chain specific polyclonal antibodies (Fig 2A, lanes 4 and 5). As
shown in Fig 2(B), the binding of 125I-labeled NC1 was completely
inhibited by the J-18 antibody (compare bar NONE with bar J-
18). Like the presence of the J-18 antibody, the presence of a 50-fold
excess of unlabeled NC1 also completely blocked the interaction
between labeled NC1 and laminin 5 (compare bar NONE with
bar NC1). NC1 binding to laminin 5 was also inhibited by µ60%
with K140, a monoclonal antibody to the β3 chain (compare bar
NONE with bar K140). In contrast, MoAb BM165, which
specifically recognizes only the α3 chain and control normal rabbit
serum, did not inhibit the interaction between laminin 5 and NC1
(compare bar NONE with bars BM165 and NIgG). These data
suggest that the β3 chain of laminin 5 is involved in the NC1–
laminin 5 interaction.
We have previously shown that NC1 is N-linked glycosylated
(Chen et al, 1997a). To examine whether N-linked glycosylation
plays a role in NC1 binding to laminin 5, the purified recombinant
NC1 was deglycosylated with peptide N-glycosidase F and then
tested for its ability to bind laminin 5. As shown in Fig 2(B), the
presence of a 50-fold excess of unlabeled deglycosylated NC1
completely abolished the interaction between labeled NC1 and
laminin 5 (compare bar NONE with bar NC1*). This indicates
Figure 1. Solid phase binding of NC1 to laminin 5. (A) BSA, human
laminin 1 [L1 (H)], mouse laminin 1 [L1 (M)], human laminin 5 [L5 (H)],
rat laminin 5 [L5 (R)] were plated onto an enzyme-linked immunosorbant
assay plate at 10 µg per ml. Two micrograms of purified authentic NC1
(solid bar) or recombinant NC1 (shadow bar) were incubated with each
protein overnight in PBST at 4°C. Binding was detected using a monoclonal
anti-NC1 antibody LH 7.2 (1:300), followed by an alkaline phosphatase-
conjugated secondary antibody (1:400). These data represent the mean
6 SD of triplicate determinations in one representative experiment. Similar
results were obtained in two other independent experiments. (B) Enzyme-
linked immunosorbent assay plates were coated with either human laminin
5 [L5 (H)], rat laminin 5 [L5 (R)], or BSA (10 µg per ml) and incubated
with the indicated concentrations of 125I-NC1. Each data point is an
average of three independent observations. The variance between these
observations was less than 8%.
that N-linked glycosylation of NC1 is not required for its affinity
for laminin 5.
Binding of NC1 to b and g chains of laminin 5 in the protein
overlay assay Laminin-5 is a heterotrimer composed of three
nonidentical α, β, and γ polypeptide chains. To further investigate
which chain(s) of laminin 5 interacts with NC1, the binding of
125I-NC1 to laminin 5 was studied by a protein overlay assay using
laminin 5 that had been reduced and electrophoretically separated
on SDS polyacrylamide gels and transferred to nitrocellulose. The
specificity of this assay was tested by evaluating the relative binding
of albumin, fibronectin, type IV collagen, human laminin 1, and
mouse laminin 1 to 125I-NC1 on the same blot. As shown in
Fig 3(A), 125I-NC1 bound strongly to the 140 kDa β3 chain of
laminin 5. It also bound weakly to the 155 kDa γ2 chain. No
detectable binding, however, was observed to the 200 kDa α3
chain or the 165 kDa processed α3* chain (Fig 3A, lanes 6 and
7). Albumin, type IV collagen, human laminin 1, and mouse
laminin 1 also failed to bind NC1 (Fig 3A, lanes 1, 3–5).
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Figure 2. Inhibition of 125I-NC1 binding to immobilized laminin
5. (A) Two micrograms of human laminin 5 purified from keratinocyte
ECM was subjected to 6% SDS-PAGE and Coomassie Blue staining (lane
2), or immunoblotting with a polyclonal antibody J-18 (lane 3), a polyclonal
antibody to γ2 chain (lane 4), and a polyclonal antibody to β3 chain (lane
5). Lane 1 is CB staining of molecular mass markers. The positions of the
molecular mass markers and the α3, α3*, β3, and γ2 chains of laminin 5
are indicated. (B) Microtiter wells coated with laminin 5 (10 µg per ml)
were preincubated with a β3 chain-specific monoclonal antibody, K140
(0.15 mg per ml); an α3 chain-specific monoclonal antibody, BM165
(0.15 mg per ml); a polyclonal antibody, J-18 (1:100); normal rabbit serum
NIgG (1:100); or a 50-fold excess of unlabeled NC1 or deglycosylated
NC1* for 2 h at room temperature, followed by incubation with 50 ng of
radiolabeled 125I-NC1. Results are shown as the percentage of radioactivity
bound to the wells after substracting the BSA coated wells after 4 h
incubation at 4°C. These data represent the mean 6 SD of triplicate
determinations in a representative experiment. Similar results were obtained
in two other independent experiments.
To further evaluate the specificity of NC1 binding to the β3
and γ2 chains of laminin-5, 125I-NC1 incubations were carried out
in the presence of a 0-, 50-, or 100-fold excess of unlabeled NC1
or a 1000-fold and 2000-fold excess of unrelated proteins such as
BSA and laminin 1. As demonstrated in Fig 3(B), the presence of
unlabeled NC1 inhibits the 125I-NC1 binding to the β3 or γ2
chains of human laminin 5 (Fig 3B, lanes 6 and 7), whereas the
presence of albumin and laminin 1 does not (Fig 3B, lanes 2–5).
Furthermore, the binding of 125I-NC1 to the laminin 5 chains was
inhibited by the presence of J-18, the anti-laminin 5 antibody, but
not by control normal rabbit serum (Fig 3B, lanes 8 and 9).
Deletion analysis of the laminin 5 binding site within
NC1 Sequence analysis of the NC1 revealed the presence of
multiple submodules with homology to adhesive proteins (Christi-
ano et al, 1992, 1994). This suggested that these submodules of
Figure 3. Binding of 125I-NC1 to laminin 5 in protein overlay assay.
(A) Shown are nitrocellulose transfers containing SDS-polyacrylamide
gel electrophoretically separated proteins overlaid with 125I-NC1. These
proteins include BSA (lane 1), fibronectin (Fin) (lane 2), type IV collagen
(CIV) (lane 3), mouse laminin 1 [L1 (M)] (lane 4), human laminin 1 [H
(L1)] (lane 5), rat laminin 5 [L5 (R)] (lane 6), and human laminin 5 [L5
(H)] (lane 7). The positions of the molecular mass markers and the β3 and
γ2 chains of laminin 5 are indicated. (B) Shown are nitrocellulose transfers
containing 2 µg of human laminin 5 in each lane, which were overlaid
with 125I-NC1 in the absence (None) (lane 1) or presence of 1000-fold or
2000-fold excesses (wt/wt) of BSA (lanes 2 and 3) and laminin 1 (L1)
(lanes 4 and 5), or in the presence of 50- or 100-fold excesses of unlabeled
NC1 (lanes 6 and 7), or in the presence of normal rabbit serum NIgG
(1:200) (lane 8) and a polyclonal antibody J-18 to the laminin 5 (1:200)
(lane 9).
the NC1 domain might mediate interactions with other matrix
components within the lamina densa and papillary dermis. In order
to identify which of these submodules are necessary for NC1 to
bind to laminin 5, we made two deletion cDNA constructs, NC1-
S1 and NC1-S2, from the carboxyl-terminal of the NC1 domain
(Fig 4A), transfected them into 293 cells, and isolated stably
transfected 293 clones. Recombinant proteins were then purified
from serum free culture medium, as described for full-length NC1
(Chen et al, 1997a). As shown in Fig 4(B), purified recombinant
proteins had apparent molecular masses of 145 kDa for NC1,
120 kDa for NC1-S1, and 86 kDa for NC1-S2. These were the
masses expected from the respective cDNA inserts. The binding
activities of these recombinant deletion proteins were then analyzed
by the protein overlay assay. As shown in Fig 5(A), the binding
of 125I-NC1 to laminin 5 was inhibited by the inclusion of a 50-
fold excess of unlabeled full-length NC1 or NC-S1 containing a
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Figure 4. Domain organization and construction of NC1 mutants
recombinant proteins. (A) Schematic diagram of the recombinant
proteins created by selected deletions from the NC1 cDNA. The 1253-
amino acid sequence of NC1 has motifs with homology to known adhesive
proteins including cartilage matrix protein, nine FNIII 1–9, and the VWF-
A. Two additional deletion mutant recombinant proteins are shown in the
schematic with the amino acid residue numbers indicated. (B) NC1 mutant
proteins were purified from 293 cell clones and subjected to 6% SDS-
PAGE followed by Coomassie Blue staining (CB) and western blot analysis
(WB) with monoclonal antibody LH7.2. The positions of the molecular
mass marker are indicated.
deletion of the VWF-A domain (Fig 5A, lanes 2 and 3). In contrast,
the NC1-S2 containing a further deletion (residues 760–1045) did
not compete with the 125I-NC1 binding to laminin 5 (Fig 5A,
lane 4). The ability of NC1-S2 to bind to laminin 5 was further
examined using the solid-phase ligand binding assay. As shown in
Fig 5(B), consistent with the overlay protein binding assay, NC1
again demonstrated affinity for laminin 5. In contrast, NC1-S2 was
incapable of binding to laminin 5. Taken together, these results
indicate that the active region for laminin 5 binding within the
NC1 domain is located between the sixth and ninth FNIII repeats
(residues 760–1045).
Inhibition of NC1/laminin 5 interaction with EBA
serum EBA is a severe blistering skin disease in which the
epidermis separates from the dermis at the BMZ. Because EBA
often occurs with minimal clinical or histologic inflammation, it has
been hypothesized that the defective epidermal–dermal adherence in
EBA involves autoantibody targeting of functional epitopes causing
interference with the normal interactions between NC1 and its
ECM ligands (Woodley et al, 1987; Chen et al, 1997a). In the
context of this investigation, we sought to determine if IgG from
EBA serum would perturb the interaction between NC1 and
laminin 5. To examine this possibility, 125I-NC1 was preincubated
with IgG from EBA serum or control normal human serum
Figure 5. Laminin-binding properties of deletion NC1 mutant
proteins. (A) Shown are nitrocellulose transfers containing 2 µg of human
laminin 5 in each lane that were overlaid with 125I-NC1 in the absence
(NONE) (lane 1) or presence of 40-fold excesses (wt/wt) of nonradioactive
NC1 (lane 2), NC1-S1 (lane 3), or NC1-S2 (lane 4). (B) Enzyme-linked
immunosorbant assay plates were coated with 2 µg of purified recombinant
NC1 and NC1-S2 and incubated with the indicated concentrations of
purified laminin 5. A polyclonal antibody to laminin 5 and an alkaline
phosphatase-conjugated secondary antibody, were used to detect the
amount of bound substrates. Each data point is an average of three
independent observations.
and then reacted with nitrocellulose strips containing 2 µg of
immobilized laminin 5. As demonstrated in Fig 6(A), the presence
of 100 µg EBA IgG per ml, but not normal serum IgG, inhibited
the binding of 125I-NC1 to laminin 5. This suggests that the
presence of EBA IgG perturbs the interaction between NC1 and
laminin 5.
We have previously produced a series of GST fusion proteins
encompassing the complete NC1 domain of type VII collagen
(Lapiere et al, 1993). These recombinant type VII collagen fusion
proteins (Fig 6B) were then used to identify regions within NC1
that were recognized by EBA serum. As shown in Fig 6(C), the
EBA IgG used in this study recognized two major antigenic
epitopes within NC1, because it bound to FP1 and FP7 by western
analysis (Fig 6C, lanes 1 and 3). This binding was specific, because
the EBA IgG did not recognize FP4 and FP8 (Fig 6C, lanes 2 and
4). Furthermore, control normal human serum did not react with
any of the fusion proteins tested (data not shown). Interestingly,
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Figure 6. Inhibition of 125I-NC1 binding to laminin 5 by EBA serum. (A) Shown are nitrocellulose transfers containing 2 µg of human laminin 5
that were overlaid with 125I-NC1. 125I-NC1 was preincubated for 2 h at room temperature with 100 µg EBA serum (EBA) per ml or normal human
serum (NHS) before testing the 125I-NC1 binding to laminin 5. (B) The positions of four fusion proteins that correspond to the NC1 are shown in the
schematic with the amino acid residue numbers indicated. (C) Western immunoblot of the fusion proteins with EBA serum. Purified recombinant fusion
proteins FP1 (lane 1), FP3 (lane 2), FP7 (lane 3), and FP8 (lane 4) were subjected to 10% SDS-PAGE followed by western blot analysis with EBA serum
(1:100). The positions of the molecular mass markers are indicated.
the FP7 epitope region lies within residues 814 and 1028 that
colocalize with the NC1 region that binds to laminin 5 (residues
760–1045).
DISCUSSION
In this study, we demonstrated that the NC1 domain of the type
VII collagen alpha chain binds to laminin 5. This extends a recent
study by Rousselle et al (1997) and our earlier study (Chen et al,
1997a), which demonstrated specific binding between NC1 and a
complex of laminin 5 and laminin 6. The specificity of this
interaction was demonstrated by the lack of NC1 interaction with
laminin 1 and BSA and by the lack of binding of labeled NC1 to
laminin 5 in the presence of excess unlabeled NC1, but not other
proteins. The interaction also could be inhibited with a monoclonal
antibody to the β3 chain of laminin 5 (K140) and an anti-laminin
5 polyclonal antibody, but not by a monoclonal antibody (BM165)
to the α3 chain. Additionally, in an independent gel-overlay protein
binding assay, we directly demonstrated that NC1 binds to laminin
5 predominately via the β3 chain. Using a panel of purified
recombinant NC1 deletion proteins, we also mapped the laminin
5-binding site within the NC1 domain to a region between FNIII
7 and FNIII 9.
It has been suggested that anchoring fibrils associate with
hemidesmosomes via putative interactions between the NC1
domain of type VII collagen and the components of anchoring
filaments (Burgeson, 1987) such as laminin 5. From the available
evidence, it has been hypothesized that laminin 5 is oriented in
the basement membrane with its carboxyl-terminal α3 G-domain
located adjacent to the basal cell surface and apposed to the
hemidesmosome integrin receptor, α6β4 (Baker et al, 1996b; Green
and Jones, 1996). In this model, the amino-terminal truncated
short arms of laminin 5 face the lamina densa and the β3 and γ2
chains interact with NC1 (Rousselle et al, 1997). Our data directly
demonstrate that the β3 and γ2 chains of laminin 5 are involved
in this interaction. Antibody blocking experiments showed that a
β3 chain-specific monoclonal antibody, K140, was able to inhibit
the binding of NC1 to laminin 5. In contrast, an α3 chain-specific
monoclonal antibody, BM 165, had no inhibitory effect. This
strongly suggests that one of the NC1 binding sites on laminin 5
is within the β3 chain.
The K140 monoclonal antibody to the β3 chain did not
completely abolish the NC1–laminin 5 interaction. There may be
multiple NC1-binding sites on the β3 chain, and the K140
monoclonal antibody may only block one of them. In addition,
our data suggest that although the β3 chain may predominantly
mediate the NC1 binding, the γ2 chain also may contribute to the
NC1 affinity. In the protein overlay binding assay, the labeled NC1
bound strongly to the β3 chain, and also bound to the γ2 chain,
but much less so. In addition, in the antibody blocking experiments,
a polyclonal antibody to laminin 5 (which reacts with both the β3
and γ2 chains) completely abolished the NC1–laminin 5 interaction.
Taken together, these data support the notion that although the
β3 chain may contain the predominant NC1-binding domain, the
γ2 chain also plays a role in mediating the NC1-laminin 5 affinity.
The fact that NC1 interacts with both human and rat laminin 5
suggests that the NC1-binding domains of laminin 5 are conserved
between these two species.
In our previous study (Chen et al, 1997a), we demonstrated that
both authentic and recombinant NC1 specifically bound to type I
collagen, type IV collagen, and fibronectin by a solid-phase binding
assay. In the present overlay-protein binding assay, however, NC1
did not bind to type IV collagen and fibronectin (Fig 3A). Because
type IV collagen and fibronectin were reduced and denatured in
the protein overlay assay, our data suggest that a native conformation
of type IV collagen and fibronectin is required for the NC1
interaction.
Laminin 5 binding sites within NC1 were mapped to the 285
amino acid residues between the seventh and nineth FNIII repeats
within NC1, an area distinct from the collagen binding site
(unpublished observation). In keeping with these data, a recent
study (Rousselle et al, 1997) showed that type XII and XIV
collagens do not interact with laminin 5, although they share both
FNIII and VWF-A motifs with the NC1 domain of type VII
collagen. Therefore, the subdomain within the seventh and nineth
FNIII may contain the specific sequences that are responsible for
binding to laminin 5. In this regard, it is interesting to note that
previous epitope mapping studies (Gammon et al, 1993; Lapiere
et al, 1993) identified four major antigenic epitopes recognized by
autoantibodies in the sera from EBA patients. One antigenic epitope
resides within the seventh and nineth FNIII repeats.
Furthermore, in this study, we demonstrated that the NC1/
laminin 5 interaction could be abrogated by the presence of EBA
IgG but not IgG from normal human serum. Epitope mapping of
this EBA serum showed that the autoantibodies recognized two
distinct NC1 sites, and one of these colocalized precisely with the
binding site for laminin 5. These data support the hypothesis that
EBA autoantibodies may contribute to defective epidermal–dermal
adhesion by the relatively novel pathomechanism of targeting
functional epitopes within important matrix adherence proteins.
Thus, autoantibodies to the NC1 domain of type VII collagen may
interfere with the normal interactions between type VII collagen
and its ECM ligand(s) in the basement membrane zone or the
papillary dermis; in this case to laminin 5, a component of
anchoring filaments.
The biologic implication of the in vivo NC1–laminin 5 interaction
remains an open question. Laminin 5 and NC1 can be isolated as
a complex from collagenase-digested amnion (Rousselle et al, 1997).
These data suggest that the strong affinity of NC1 to laminin 5
seen in vitro is physiologically significant. Molecular defects in genes
encoding for type VII collagen or laminin 5 in humans result in
severe blistering disorders of the skin. Likewise, autoantibodies
against either type VII collagen or laminin 5 result in acquired
incurable blistering diseases of the skin. These naturally occurring
diseases demonstrate the importance of type VII collagen and
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laminin 5 in maintenance of the DEJ and epidermal–dermal
adherence.
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